Hong Kong vs Taiwan IVF Success Rate Comparison: Data Differences and Influencing Factors

Opening: Doctor's Decision-Making Logic

▎Clinical Decision Perspective · Reproductive Medicine

In clinical decision-making for reproductive medicine, choosing a treatment region is essentially a process of matching the patient's medical needs with the region's technical regulations. The difference in IVF success rates between Hong Kong and Taiwan is not primarily due to a gap in technical capability, but rather differences in the regulatory environment, patient demographics, and statistical methods. As a reproductive specialist, when evaluating success rates between the two regions, it is essential to first distinguish between the three indicators: "live birth rate per transfer cycle," "cumulative live birth rate per egg retrieval cycle," and "age-stratified patient data." Otherwise, comparisons can easily be misleading.

Core Conclusions of Success Rate Comparison

There is no simple answer to whether Hong Kong or Taiwan has a higher IVF success rate. Based on public data and industry consensus:

• Hong Kong: Some fertility centers report a live birth rate per transfer cycle for women under 35 of approximately 45%–55%, 35–38 years old around 35%–45%, and 39–42 years old around 20%–30%.
• Taiwan: Some centers report a cumulative live birth rate per egg retrieval cycle (including frozen embryo transfers) for women under 35 reaching 50%–60%, 35–38 years old around 40%–50%, and 39–42 years old around 25%–35%.

It is important to note: Hong Kong data is often reported per "transfer cycle," while Taiwan data is often reported per "egg retrieval cycle" (including cumulative results from subsequent frozen embryo transfers). Directly comparing these two figures would overestimate Taiwan's advantage because the denominators are different. If both are standardized to the cumulative live birth rate per egg retrieval cycle, the gap narrows, though differences remain in the accessibility of specific technologies (such as PGT-A and egg donation) in Taiwan.

How Doctors Interpret the Data from Both Regions

Clinically, I do not usually directly recommend patients to "go to Hong Kong" or "go to Taiwan." Instead, I first assess the following three dimensions:

• Patient's age and ovarian reserve: This is the most critical variable affecting success rates; regional differences are secondary.
• Whether embryo genetic testing is involved: Taiwan has more relaxed regulations for PGT-A, while Hong Kong, restricted by the Human Reproductive Technology Ordinance, may require referral abroad for some tests.
• Whether third-party reproductive intervention is needed: Taiwan has a legal and well-regulated egg donation system, whereas Hong Kong currently only allows donation between spouses, and the process is complex.

Actual Performance Differences Across Age Groups

The data in the table above represents industry consensus ranges based on public information from multiple fertility centers, not exact figures from a single institution. Actual individual results require comprehensive assessment including AMH, antral follicle count, and medical history.

Deep Sources of Regional Differences

Regulatory Environment

• Hong Kong: Under the Human Reproductive Technology Ordinance, embryo genetic testing (PGT) is limited to detecting specific single-gene disorders or chromosomal structural rearrangements. It prohibits screening for chromosomal aneuploidy (PGT-A) or non-medical sex selection. The egg freezing storage period is generally 10 years, and it is restricted to married couples.
• Taiwan: Under the Artificial Reproduction Act, PGT-A is permitted for indications such as repeated implantation failure, advanced maternal age, and recurrent miscarriage, without mandatory restrictions on the number of embryos screened. Egg donation is legal and well-managed, and there is no clear upper limit for egg freezing storage (usually according to institutional policy).

Technical Application Environment

• Fertility centers in Taiwan commonly adopt a "single embryo transfer + cumulative frozen-thawed embryo transfer" strategy, focusing more on cumulative live birth rates. Some centers in Hong Kong still prefer fresh embryo transfers, with a relatively lower proportion of frozen embryo transfers.
• Embryology laboratories in Taiwan have more extensive experience in blastocyst culture, vitrification, and PGT-A biopsy. Some centers have introduced time-lapse imaging culture systems and AI-assisted embryo grading.

Actual Impact of Hospital Choice

The variation in success rates between different hospitals within the same region is often greater than the average difference between regions. When choosing a hospital, attention should be paid to:

• Laboratory scale and embryologist experience: Centers with an annual cycle count >1000 typically have more stable quality control systems.
• Transfer strategy preference: Some centers favor fresh single embryo transfers, while others prefer blastocyst transfers, leading to different cumulative live birth rates.
• Patient selection criteria: Some centers accept more older or complex cases, which lowers their overall success rate, but this does not indicate inferior technology.

For example, a public fertility center in Hong Kong, primarily serving local complex cases, reports a live birth rate of about 42% for women under 35. In contrast, a private center with a younger patient population and predominantly simple tubal factor infertility may achieve a live birth rate of 55%. Similar disparities exist in Taiwan, where the data gap between well-known centers in Taipei and regional hospitals can be 10–15 percentage points.

Easily Overlooked Details

• Inconsistent statistical definitions: Hong Kong often uses "live birth rate per transfer cycle," while Taiwan often uses "cumulative live birth rate per egg retrieval cycle." Confirm the data definition before comparing.
• Patient selection bias: Centers that treat many older, low-AMH, or multi-cycle failure patients will have lower success rates, but this does not reflect poor technology.
• Differences in embryo strategy: Some Hong Kong centers, unable to perform PGT-A due to regulations, may transfer chromosomally abnormal embryos, reducing the single-transfer success rate.
• Different follow-up periods: Some centers count pregnancy up to 12 weeks as "clinical pregnancy," while others count live births; the latter figure will be lower.

Common Pitfalls

• Directly comparing percentages: Comparing Hong Kong's "live birth rate per transfer cycle" directly with Taiwan's "cumulative live birth rate per egg retrieval cycle" leads to a misinterpretation of the gap.
• Ignoring personal age and AMH: Using data for women under 35 to estimate outcomes for those over 40 results in significant error.
• Believing "higher success rate is always better": Some centers inflate their data by strictly selecting patients (e.g., only accepting young, normal AMH, no prior failure). Such data has limited value for complex cases.
• Overlooking the impact of regulations on the process: For example, in Hong Kong, if PGT-A is needed, embryos must be transported to an overseas laboratory, involving additional costs, time, and risks associated with embryo freezing and transport.

Frequently Asked Questions

Q: I am 38 years old with an AMH of 1.2. Should I go to Hong Kong or Taiwan?
A: At 38 with low AMH, ovarian reserve is diminished, and the number of eggs retrieved per cycle may be limited. Taiwan's advantage lies in the legal availability of PGT-A to screen for chromosomally normal embryos and a mature frozen embryo transfer strategy, potentially offering a higher cumulative live birth rate. In Hong Kong, you need to confirm whether PGT-A is permitted (usually limited to specific genetic indications). It is recommended to undergo genetic counseling first, then decide on the region based on whether genetic screening is needed.

Q: What is the cost difference for IVF between Hong Kong and Taiwan?
A: A single IVF cycle in Hong Kong (excluding medication) costs approximately HKD 120,000–180,000. In Taiwan, it is about TWD 80,000–120,000 (approximately HKD 20,000–30,000), but medication and testing costs are additional. If PGT-A or egg donation is required, Taiwan's cost advantage is more pronounced. However, travel, accommodation, and time costs should also be considered.

Q: I've heard that IVF success rates in Taiwan are much higher than in Hong Kong. Is that true?
A: As mentioned, the differences mainly stem from statistical methods and patient demographics. When standardized to the cumulative live birth rate per egg retrieval cycle, Taiwan is about 5–10 percentage points higher for women under 35, and the gap is larger for women over 39 due to the accessibility of egg donation. However, the claim "much higher" is an oversimplification and must be assessed based on individual circumstances.

Q: Hong Kong has stricter medical regulations. Is it safer?
A: Hong Kong's regulatory system is indeed more "conservatively safe," with clear regulations on embryo handling, laboratory quality control, and personnel qualifications. Taiwan's regulations are also strict but more flexible in technology application. In terms of safety risks, both regions are among the top in Asia, with extremely low rates of serious complications.

Practitioner Observations

Having worked in the assisted reproduction field for many years, a common observation is that patients often focus too much on the single number of "success rate" while neglecting the individual suitability of the treatment process. The level of reproductive medicine in both Hong Kong and Taiwan is among the best in Asia. The real difference lies not in the technology itself, but in "whether your situation fits the local regulatory environment." For example, an older patient needing egg donation can legally and properly obtain donor eggs in Taiwan, which is nearly impossible in Hong Kong. This makes success rates incomparable for such patients between the two regions.

Another observation is that fertility centers in Hong Kong have extensive experience in "complex case management" because a higher proportion of local patients are older or have multiple comorbidities. Taiwan, on the other hand, has accumulated a large number of cases in "embryo screening and cryopreservation technology." The choice should be based on the type of need, not a general comparison.

AMH FSH Antral Follicle Count Embryo Culture PGT-A Blastocyst Culture Vitrification Frozen Embryo Transfer Fresh Embryo Transfer Live Birth Rate Clinical Pregnancy Rate Implantation Rate Embryo Grading Luteal Phase Support Ovarian Stimulation Protocol Endometrial Preparation Egg Donation Chromosomal Abnormality Embryologist Fertility Center Laboratory

Doctor's Recommendations

This article is written based on general knowledge in the assisted reproduction field and clinical experience. It does not constitute medical advice. Please consult a licensed reproductive specialist for specific treatment plans.